Adil Daud, MD
Professor
Medicine
School of Medicine

Immune therapy and Clinical Trials

Education & Training

Show all (4) Hide

• Residency Internal Medicine Indiana University 06/1997
• Post Doc Fellowship Molecular Biology Indiana University 6/1994
• Post Doc Fellowship Biochemistry Cleveland Clinic 12/1989
• MBBS Medicine Government Medical College 12/1985

Websites

Show all (3) Hide

• @@ad1600 on Twitter (twitter.com)
• Clinical Profile at UCSF Medical Center (ucsfhealth.org)
• Profile at UCSF Cancer Center (cancer.ucsf.edu)

Publications (202)

Top publication keywords:
Interleukin-12Antineoplastic AgentsAntineoplastic Agents, ImmunologicalProto-Oncogene Proteins B-rafMelanomaAntineoplastic Combined Chemotherapy ProtocolsProgrammed Cell Death 1 ReceptorIpilimumabPyrimidinonesCTLA-4 AntigenImmunotherapyAntibodies, Monoclonal, HumanizedSkin NeoplasmsProtein Kinase InhibitorsB7-H1 Antigen

• Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Algazi AP, Twitty CG, Tsai KK, Le M, Pierce R, Browning E, Hermiz R, Canton DA, Bannavong D, Oglesby A, Francisco M, Fong L, Pittet MJ, Arlauckas SP, Garris C, Levine LP, Bifulco C, Ballesteros-Merino…
• Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients.
  Annals of oncology : official journal of the European Society for Medical Oncology 2020 Algazi A, Bhatia S, Agarwala S, Molina M, Lewis K, Faries M, Fong L, Levine LP, Franco M, Oglesby A, Ballesteros-Merino C, Bifulco CB, Fox BA, Bannavong D, Talia R, Browning E, Le MH, Pierce RH, …
• Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Bhatia S, Longino NV, Miller NJ, Kulikauskas R, Iyer JG, Ibrani D, Blom A, Byrd DR, Parvathaneni U, Twitty CG, Campbell JS, Le MH, Gargosky S, Pierce RH, Heller R, Daud AI, Nghiem P
• A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma.
  Pigment cell & melanoma research 2019 Algazi AP, Rotow J, Posch C, Ortiz-Urda S, Pelayo A, Munster PN, Daud A
• Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.
  Annals of oncology : official journal of the European Society for Medical Oncology 2019 Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph R, Weber JS, Dronca R, Mitchell TC, Patnaik A, Zarour HM, Joshua AM, Zhao Q, Jensen E, Ahsan S, Ibrahim N, Ribas A
• Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019 Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, Friedlander PA, Daud A, Kluger HM, Reddy SA, Boulmay BC, Riker AI, Burgess MA, Hanks BA, Olencki T, Margolin K, Lundgren LM, Soni A…
• Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.
  Immunity 2018 Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M, Gungabeesoon J, Freeman GJ, Warren SE, Ong S, Browning E, Twitty CG, Pierce RH, Le MH, Algazi AP, …
• Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.
  European journal of cancer (Oxford, England : 1990) 2018 Carlino MS, Long GV, Schadendorf D, Robert C, Ribas A, Richtig E, Nyakas M, Caglevic C, Tarhini A, Blank C, Hoeller C, Bar-Sela G, Barrow C, Wolter P, Zhou H, Emancipator K, Jensen EH, Ebbinghaus S, …
• A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments.
  Nature medicine 2018 Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, Nelson AE, Loo K, Kumar R, Rosenblum MD, Alvarado MD, Wolf DM, Bogunovic D, Bhardwaj N, Daud AI, Ha PK, Ryan WR, Pollack JL, Samad B, …
• Negative but not futile: MAGE-A3 immunotherapeutic for melanoma.
  The Lancet. Oncology 2018 Daud AI
• Revisiting RECIST: the case of treatment beyond progression.
  The Lancet. Oncology 2018 Daud AI
• Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma.
  Pigment cell & melanoma research 2017 Algazi AP, Esteve-Puig R, Nosrati A, Hinds B, Hobbs-Muthukumar A, Nandoskar P, Ortiz-Urda S, Chapman PB, Daud A
• Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy.
  JCI insight 2017 Loo K, Tsai KK, Mahuron K, Liu J, Pauli ML, Sandoval PM, Nosrati A, Lee J, Chen L, Hwang J, Levine LS, Krummel MF, Algazi AP, Pampaloni M, Alvarado MD, Rosenblum MD, Daud AI
• Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC.
  Cancer immunology research 2017 Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, Rosenblum M, Harview CL, Taube JM, Handley N, Khurana N, Nosrati A, Krummel MF, Tucker A, Sosa EV, Sanchez PJ, Banayan N, Osorio JC, Nguyen-…
• Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy.
  British journal of cancer 2017 Nosrati A, Tsai KK, Goldinger SM, Tumeh P, Grimes B, Loo K, Algazi AP, Nguyen-Kim TDL, Levesque M, Dummer R, Hamid O, Daud A
• Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.
  British journal of cancer 2017 Daud A, Kluger HM, Kurzrock R, Schimmoller F, Weitzman AL, Samuel TA, Moussa AH, Gordon MS, Shapiro GI
• Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients.
  Journal of hematology & oncology 2017 Daud A, Gill J, Kamra S, Chen L, Ahuja A
• Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs.
  Cancer journal (Sudbury, Mass.) 2017 Loo K, Daud AI
• Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 Daud AI, Wolchok JD, Robert C, Hwu WJ, Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, Joseph R, Gangadhar TC, Dronca R, Patnaik A, Zarour H, Roach C, Toland G, Lunceford JK, Li XN, …
• Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.
  The Journal of clinical investigation 2016 Daud AI, Loo K, Pauli ML, Sanchez-Rodriguez R, Sandoval PM, Taravati K, Tsai K, Nosrati A, Nardo L, Alvarado MD, Algazi AP, Pampaloni MH, Lobach IV, Hwang J, Pierce RH, Gratz IK, Krummel MF, Rosenblum…

Show all (182 more) Hide

• Targeted DNA Sequencing of Cutaneous Melanoma Identifies Prognostic and Predictive Alterations.
  Cancers 2024 Haugh AM, Osorio RC, Francois RA, Tawil ME, Tsai KK, Tetzlaff M, Daud A, Vasudevan HN
• Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors.
  World journal of surgical oncology 2024 Wong P, Wisneski AD, Tsai KK, Chang TT, Hirose K, Nakakura EK, Daud AI, Maker AV, Corvera CU
• Current Role and Status for Intratumoral Injection Therapies in Metastatic Melanoma.
  Cancer journal (Sudbury, Mass.) 2024 Haugh AM, Daud AI
• The therapeutically actionable long non-coding RNA 'T-RECS' is essential to cancer cells' survival in NRAS/MAPK-driven melanoma.
  Molecular cancer 2024 Feichtenschlager V, Chen L, Zheng YJ, Ho W, Sanlorenzo M, Vujic I, Fewings E, Lee A, Chen C, Callanan C, Lin K, Qu T, Hohlova D, Vujic M, Hwang Y, Lai K, Chen S, Nguyen T, Muñoz DP, Kohwi Y, Posch C, …
• Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma.
  American journal of clinical dermatology 2024 Haugh A, Daud AI
• The therapeutically actionable long non-coding RNA 'T-RECS' is essential to cancer cells' survival in NRAS/MAPK-driven melanoma.
  Research square 2023 Feichtenschlager V, Chen L, Zheng YJ, Ho W, Sanlorenzo M, Vujic I, Fewings E, Lee A, Chen C, Callanan C, Lin K, Qu T, Hohlova D, Vujic M, Hwang Y, Lai K, Chen S, Nguyen T, Muñoz DP, Kohwi Y, Posch C, …
• Pembrolizumab-associated chronic rhinosinusitis: A new endotype and management considerations.
  International forum of allergy & rhinology 2023 Standiford TC, Patel NN, Singh A, Gochman G, Jamie Wu T, Daud AI, Goldberg AN
• Resistance to Immune Checkpoint Blockade: IFNγ or MHC-I?
  Cancer immunology research 2023 Haugh A, Daud A
• Pulsed Electric Fields in Oncology: A Snapshot of Current Clinical Practices and Research Directions from the 4th World Congress of Electroporation.
  Cancers 2023 Campana LG, Daud A, Lancellotti F, Arroyo JP, Davalos RV, Di Prata C, Gehl J
• Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 Robert C, Carlino MS, McNeil C, Ribas A, Grob JJ, Schachter J, Nyakas M, Kee D, Petrella TM, Blaustein A, Lotem M, Arance A, Daud AI, Hamid O, Larkin J, Anderson J, Krepler C, Grebennik D, Long GV
• Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma.
  Cancer chemotherapy and pharmacology 2023 Rasco DW, Medina T, Corrie P, Pavlick AC, Middleton MR, Lorigan P, Hebert C, Plummer R, Larkin J, Agarwala SS, Daud AI, Qiu J, Bozon V, Kneissl M, Barry E, Olszanski AJ
• Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 de Braud F, Dooms C, Heist RS, Lebbe C, Wermke M, Gazzah A, Schadendorf D, Rutkowski P, Wolf J, Ascierto PA, Gil-Bazo I, Kato S, Wolodarski M, McKean M, Muñoz Couselo E, Sebastian M, Santoro A, Cooke …
• Retrospective study of the incidence of sarcoidosis-like reaction in patients treated with immunotherapy.
  Clinical radiology 2022 Li Y, Flavell RR, Juarez R, Chow M, Wu C, Tsai K, Daud A, Behr SC
• Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.
  Immunity 2022 Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M, Gungabeesoon J, Freeman GJ, Warren SE, Ong S, Browning E, Twitty CG, Pierce RH, Le MH, Algazi AP, …
• Melanoma risk during immunomodulating treatment.
  Melanoma research 2022 Zheng YJ, Ho W, Sanlorenzo M, Vujic I, Daud A, Algazi A, Rappersberger K, Ortiz-Urda S
• Intratumoral Electroporation of Plasmid Encoded IL12 and Membrane-Anchored Anti-CD3 Increases Systemic Tumor Immunity.
  Molecular cancer research : MCR 2022 Han M, Nguyen B, Lee JY, Browning E, Zhang J, Mukhopadhyay A, Gujar R, Salazar J, Hermiz R, Svenson L, Rolig AS, Redmond WL, Algazi AP, Daud AI, Canton DA, Twitty CG
• Intratumoral therapies and in-situ vaccination for melanoma.
  Human vaccines & immunotherapeutics 2022 Huppert LA, Daud AI
• Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity.
  Molecular therapy oncolytics 2022 Lee JY, Nguyen B, Mukhopadhyay A, Han M, Zhang J, Gujar R, Salazar J, Hermiz R, Svenson L, Browning E, Lyerly HK, Canton DA, Fisher D, Daud A, Algazi A, Skitzki J, Twitty CG
• TCR-sequencing in cancer and autoimmunity: barcodes and beyond.
  Trends in immunology 2022 Pauken KE, Lagattuta KA, Lu BY, Lucca LE, Daud AI, Hafler DA, Kluger HM, Raychaudhuri S, Sharpe AH
• Discovering dominant tumor immune archetypes in a pan-cancer census.
  Cell 2021 Combes AJ, Samad B, Tsui J, Chew NW, Yan P, Reeder GC, Kushnoor D, Shen A, Davidson B, Barczak AJ, Adkisson M, Edwards A, Naser M, Barry KC, Courau T, Hammoudi T, Argüello RJ, Rao AA, Olshen AB, …
• Response to PD-1 Immunotherapy in Metastatic Spiradenocarcinoma.
  JCO precision oncology 2021 Wu C, Chow M, Temby M, McCalmont TH, Daud A
• Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006.
  European journal of cancer (Oxford, England : 1990) 2021 Hamid O, Robert C, Daud A, Carlino MS, Mitchell TC, Hersey P, Schachter J, Long GV, Hodi FS, Wolchok JD, Arance A, Grob JJ, Joshua AM, Weber JS, Mortier L, Jensen E, Diede SJ, Moreno BH, Ribas A
• Layilin Anchors Regulatory T Cells in Skin.
  Journal of immunology (Baltimore, Md. : 1950) 2021 Mehta P, Gouirand V, Boda DP, Zhang J, Gearty SV, Zirak B, Lowe MM, Clancy S, Boothby I, Mahuron KM, Fries A, Krummel MF, Mankoo P, Chang HW, Liu J, Moreau JM, Scharschmidt TC, Daud A, Kim E, Neuhaus …
• Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy.
  Cellular & molecular immunology 2021 Huppert LA, Green MD, Kim L, Chow C, Leyfman Y, Daud AI, Lee JC
• Should Sentinel Lymph Node Biopsy Status Guide Adjuvant Radiation Therapy in Patients With Merkel Cell Carcinoma?
  Advances in radiation oncology 2021 Ahmad TR, Vasudevan HN, Lazar AA, Chan JW, George JR, Alvarado MD, Yu SS, Daud A, Yom SS
• The Liver-Immunity Nexus and Cancer Immunotherapy.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Lee JC, Green MD, Huppert LA, Chow C, Pierce RH, Daud AI
• Pembrolizumab and Ipilimumab as Second-Line Therapy for Advanced Melanoma.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021 Huppert LA, Daud AI
• Single-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichment.
  The Journal of experimental medicine 2021 Pauken KE, Shahid O, Lagattuta KA, Mahuron KM, Luber JM, Lowe MM, Huang L, Delaney C, Long JM, Fung ME, Newcomer K, Tsai KK, Chow M, Guinn S, Kuchroo JR, Burke KP, Schenkel JM, Rosenblum MD, Daud AI, …
• Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma.
  Journal for immunotherapy of cancer 2021 Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, Friedlander PA, Daud A, Kluger HM, Reddy SA, Boulmay BC, Riker A, Burgess MA, Hanks BA, Olencki T, Kendra K, Church C, Akaike T, …
• The State of Melanoma: Emergent Challenges and Opportunities.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Atkins MB, Curiel-Lewandrowski C, Fisher DE, Swetter SM, Tsao H, Aguirre-Ghiso JA, Soengas MS, Weeraratna AT, Flaherty KT, Herlyn M, Sosman JA, Tawbi HA, Pavlick AC, Cassidy PB, Chandra S, Chapman PB,…
• Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma.
  European journal of cancer (Oxford, England : 1990) 2020 Robert C, Hwu WJ, Hamid O, Ribas A, Weber JS, Daud AI, Hodi FS, Wolchok JD, Mitchell TC, Hersey P, Dronca R, Joseph RW, Boutros C, Min L, Long GV, Schachter J, Puzanov I, Dummer R, Lin J, Ibrahim N, …
• Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial.
  Nature medicine 2020 Algazi AP, Othus M, Daud AI, Lo RS, Mehnert JM, Truong TG, Conry R, Kendra K, Doolittle GC, Clark JI, Messino MJ, Moore DF, Lao C, Faller BA, Govindarajan R, Harker-Murray A, Dreisbach L, Moon J, …
• Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis.
  Science immunology 2020 Lee JC, Mehdizadeh S, Smith J, Young A, Mufazalov IA, Mowery CT, Daud A, Bluestone JA
• Layilin augments integrin activation to promote antitumor immunity.
  The Journal of experimental medicine 2020 Mahuron KM, Moreau JM, Glasgow JE, Boda DP, Pauli ML, Gouirand V, Panjabi L, Grewal R, Luber JM, Mathur AN, Feldman RM, Shifrut E, Mehta P, Lowe MM, Alvarado MD, Marson A, Singer M, Wells J, Jupp R, …
• Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit.
  JAMA dermatology 2020 Grossman D, Okwundu N, Bartlett EK, Marchetti MA, Othus M, Coit DG, Hartman RI, Leachman SA, Berry EG, Korde L, Lee SJ, Bar-Eli M, Berwick M, Bowles T, Buchbinder EI, Burton EM, Chu EY, Curiel-…
• Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.
  JAMA oncology 2020 Puzanov I, Ribas A, Robert C, Schachter J, Nyakas M, Daud A, Arance A, Carlino MS, O'Day SJ, Long GV, Margolin KA, Dummer R, Schadendorf D, Lutzky J, Ascierto PA, Tarhini A, Lin J, Mogg R, Homet …
• Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer.
  Nature communications 2020 Terranova-Barberio M, Pawlowska N, Dhawan M, Moasser M, Chien AJ, Melisko ME, Rugo H, Rahimi R, Deal T, Daud A, Rosenblum MD, Thomas S, Munster PN
• Treatment of Metastatic Melanoma With Leptomeningeal Disease Using Intrathecal Immunotherapy.
  JCO oncology practice 2020 Huppert LA, Melisko ME, Glastonbury CM, Khanafshar E, Daud AI
• ASO Author Reflections: Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
  Annals of surgical oncology 2020 Mahuron KM, Levine LS, Daud AI
• Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
  Annals of surgical oncology 2020 Levine LS, Mahuron KM, Tsai KK, Wu C, Mattis DM, Pauli ML, Oglesby A, Lee JC, Spitzer MH, Krummel MF, Algazi AP, Rosenblum MD, Alvarado M, Daud AI
• Prognostic Biomarkers for Melanoma Immunotherapy.
  Current oncology reports 2020 Twitty CG, Huppert LA, Daud AI
• Regulatory T cells use arginase 2 to enhance their metabolic fitness in tissues.
  JCI insight 2019 Lowe MM, Boothby I, Clancy S, Ahn RS, Liao W, Nguyen DN, Schumann K, Marson A, Mahuron KM, Kingsbury GA, Liu Z, Munoz Sandoval P, Rodriguez RS, Pauli ML, Taravati K, Arron ST, Neuhaus IM, Harris HW, …
• Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses.
  Cancer immunology research 2019 Greaney SK, Algazi AP, Tsai KK, Takamura KT, Chen L, Twitty CG, Zhang L, Paciorek A, Pierce RH, Le MH, Daud AI, Fong L
• Intratumoral and Combination Therapy in Melanoma and Other Skin Cancers.
  American journal of clinical dermatology 2019 Oglesby A, Algazi AP, Daud AI
• Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Ribas A, Daud A, Pavlick AC, Gonzalez R, Lewis KD, Hamid O, Gajewski TF, Puzanov I, Wongchenko M, Rooney I, Hsu JJ, Yan Y, Park E, McArthur GA
• An analysis of genetic heterogeneity in untreated cancers.
  Nature reviews. Cancer 2019 Reiter JG, Baretti M, Gerold JM, Makohon-Moore AP, Daud A, Iacobuzio-Donahue CA, Azad NS, Kinzler KW, Nowak MA, Vogelstein B
• Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.
  The Lancet. Oncology 2019 Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil CM, Lotem M, Larkin JMG, Lorigan P, Neyns B, Blank CU, Petrella TM, Hamid O, Su SC, Krepler C, Ibrahim N, Long …
• Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.
  The Lancet. Oncology 2019 Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, …
• PTCH1 Mutation in a Patient With Metastatic Undifferentiated Carcinoma With Clear Cell Change.
  Journal of the National Comprehensive Cancer Network : JNCCN 2019 Tsai KK, Khurana N, McCalmont T, Daud A, Bastian B, Yeh I
• Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity.
  Cell 2019 Binnewies M, Mujal AM, Pollack JL, Combes AJ, Hardison EA, Barry KC, Tsui J, Ruhland MK, Kersten K, Abushawish MA, Spasic M, Giurintano JP, Chan V, Daud AI, Ha P, Ye CJ, Roberts EW, Krummel MF
• Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade.
  Immunity 2019 Pai CS, Huang JT, Lu X, Simons DM, Park C, Chang A, Tamaki W, Liu E, Roybal KT, Seagal J, Chen M, Hagihara K, Wei XX, DuPage M, Kwek SS, Oh DY, Daud A, Tsai KK, Wu C, Zhang L, Fasso M, Sachidanandam R…
• Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer.
  Frontiers in medicine 2018 Bridge JA, Lee JC, Daud A, Wells JW, Bluestone JA
• Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Dronca R, Hersey P, Weber JS, Patnaik A, de Alwis DP, Perrone A, Zhang J, Kang SP,…
• Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006.
  British journal of cancer 2018 Hamid O, Robert C, Ribas A, Hodi FS, Walpole E, Daud A, Arance AS, Brown E, Hoeller C, Mortier L, Schachter J, Long J, Ebbinghaus S, Ibrahim N, Butler M
• The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma.
  Scientific reports 2018 Sanlorenzo M, Vujic I, Esteve-Puig R, Lai K, Vujic M, Lin K, Posch C, Dimon M, Moy A, Zekhtser M, Johnston K, Gho D, Ho W, Gajjala A, Oses Prieto J, Burlingame A, Daud A, Rappersberger K, Ortiz-Urda S
• Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Johnson DB, Bordeaux J, Kim JY, Vaupel C, Rimm DL, Ho TH, Joseph RW, Daud AI, Conry RM, Gaughan EM, Hernandez-Aya LF, Dimou A, Funchain P, Smithy J, Witte JS, McKee SB, Ko J, Wrangle JM, Dabbas B, …
• Immunotherapy for melanoma.
  Seminars in cutaneous medicine and surgery 2018 Cuevas LM, Daud AI
• Melanocytic Neoplasms, Introduction.
  Seminars in cutaneous medicine and surgery 2018 Daud AI
• In-field and abscopal response after short-course radiation therapy in patients with metastatic Merkel cell carcinoma progressing on PD-1 checkpoint blockade: a case series.
  Journal for immunotherapy of cancer 2018 Xu MJ, Wu S, Daud AI, Yu SS, Yom SS
• Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Dronca R, Hersey P, Weber JS, Patnaik A, de Alwis DP, Perrone A, Zhang J, Kang SP,…
• The gut microbiota and immune checkpoint inhibitors.
  Human vaccines & immunotherapeutics 2018 Humphries A, Daud A
• Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, Hwu WJ, Weber JS, Gangadhar TC, Joseph RW, Dronca R, Patnaik A, Zarour H, Kefford R, Hersey P, Zhang J, Anderson J, Diede SJ, Ebbinghaus S, …
• Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III.
  European journal of cancer (Oxford, England : 1990) 2017 Grob JJ, Schadendorf D, Lorigan P, Ascierto P, Larkin J, Nathan P, Robert C, Hauschild A, Weber J, Daud A, Hamid O, Dummer R, Hansson J, Hoeller C, Schachter J, Van Akkooi ACJ, Garbe C
• Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program.
  Journal of immunotherapy (Hagerstown, Md. : 1997) 2017 Gangadhar TC, Hwu WJ, Postow MA, Hamid O, Daud A, Dronca R, Joseph R, O'Day SJ, Hodi FS, Pavlick AC, Kluger H, Oxborough RP, Yang A, Gazdoiu M, Kush DA, Ebbinghaus S, Salama AKS
• Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
  European journal of cancer (Oxford, England : 1990) 2017 Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, Blank C, Cranmer LD, Robert C, Pavlick AC, Gonzalez R, Hodi FS, Ascierto PA, Salama AKS, Margolin KA, Gangadhar TC, Wei Z, Ebbinghaus …
• Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid).
  Immunotherapy 2017 Canton DA, Shirley S, Wright J, Connolly R, Burkart C, Mukhopadhyay A, Twitty C, Qattan KE, Campbell JS, Le MH, Pierce RH, Gargosky S, Daud A, Algazi A
• Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours.
  European journal of cancer (Oxford, England : 1990) 2017 Schöffski P, Gordon M, Smith DC, Kurzrock R, Daud A, Vogelzang NJ, Lee Y, Scheffold C, Shapiro GI
• Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Long GV, Eroglu Z, Infante J, Patel S, Daud A, Johnson DB, Gonzalez R, Kefford R, Hamid O, Schuchter L, Cebon J, Sharfman W, McWilliams R, Sznol M, Redhu S, Gasal E, Mookerjee B, Weber J, Flaherty KT
• Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
  Lancet (London, England) 2017 Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert…
• Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Larkin J, Minor D, D'Angelo S, Neyns B, Smylie M, Miller WH, Gutzmer R, Linette G, Chmielowski B, Lao CD, Lorigan P, Grossmann K, Hassel JC, Sznol M, Daud A, Sosman J, Khushalani N, Schadendorf D, …
• Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.
  Annals of oncology : official journal of the European Society for Medical Oncology 2017 Guo J, Carvajal RD, Dummer R, Hauschild A, Daud A, Bastian BC, Markovic SN, Queirolo P, Arance A, Berking C, Camargo V, Herchenhorn D, Petrella TM, Schadendorf D, Sharfman W, Testori A, Novick S, …
• Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
  The oncologist 2017 Daud A, Tsai K
• Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade.
  Journal for immunotherapy of cancer 2016 Tsai KK, Pampaloni MH, Hope C, Algazi AP, Ljung BM, Pincus L, Daud AI
• Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.
  European journal of cancer (Oxford, England : 1990) 2016 Schadendorf D, Dummer R, Hauschild A, Robert C, Hamid O, Daud A, van den Eertwegh A, Cranmer L, O'Day S, Puzanov I, Schachter J, Blank C, Salama A, Loquai C, Mehnert JM, Hille D, Ebbinghaus S, Kang SP…
• Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
  Cancer 2016 Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, Ott PA, Johnson DB, Hwang J, Daud AI, Sosman JA, Carvajal RD, Chmielowski B, Postow MA, Weber JS, Sullivan RJ
• A comparison of long-term outcomes between narrow and broad QRS complex patients treated with cardiac resynchronization therapy.
  Acta cardiologica 2016 Yap LB, Nguyen ST, Qadir F, Ma SK, Muhammad Z, Koh KW, Ali Z, Tay GS, Daud A, Said A, Sahat N, Rebo R, Tamin SS, Hussin A, Kaur S, Omar R
• Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma.
  Immunotherapy 2016 Loo K, Daud A
• Part I: Checkpoint inhibitors in cancer therapy.
  Immunotherapy 2016 Daud AI
• Part II: Checkpoint inhibitors in cancer therapy.
  Immunotherapy 2016 Daud AI
• A Review of Novel Intralesional Therapies for Melanoma, With an Emphasis on a Potential Combination Approach.
  Oncology (Williston Park, N.Y.) 2016 Chen L, Daud A
• Pembrolizumab for melanoma- safety profile and future trends.
  Expert opinion on drug safety 2016 Daud A, Nandoskar P
• Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
  JAMA 2016 Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA,…
• PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.
  The New England journal of medicine 2016 Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP, Friedlander PA, Kluger HM, Kohrt HE, Lundgren L, Margolin K, Mitchell A, Olencki T, …
• Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, Patnaik A, Ribas A, Robert C, Gangadhar TC, Joshua AM, Hersey P, Dronca R, Joseph R, Hille D, Xue D, Li XN, Kang SP, Ebbinghaus S, Perrone A, …
• A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma.
  Annals of oncology : official journal of the European Society for Medical Oncology 2016 Thomas S, Aggarwal R, Jahan T, Ryan C, Troung T, Cripps AM, Raha P, Thurn KT, Chen S, Grabowsky JA, Park J, Hwang J, Daud A, Munster PN
• Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 Long GV, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R, Sosman JA, Hamid O, Schuchter L, Cebon J, Kefford RF, Lawrence D, Kudchadkar R, Burris HA, Falchook GS, Algazi A, Lewis K, Puzanov I, Ibrahim…
• Applying the WHO conceptual framework for the International Classification for Patient Safety to a surgical population.
  International journal for quality in health care : journal of the International Society for Quality in Health Care 2016 McElroy LM, Woods DM, Yanes AF, Skaro AI, Daud A, Curtis T, Wymore E, Holl JL, Abecassis MM, Ladner DP
• Combined dabrafenib and trametinib therapy in metastatic melanoma and organ transplantation: Case report and review of the literature.
  JAAD case reports 2015 Garrett GL, He SY, Sabouni N, Daud A, Arron ST
• Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression.
  JAMA dermatology 2015 Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, Lin K, Quaglino P, Rappersberger K, Ortiz-Urda S
• Nivolumab plus ipilimumab in the treatment of advanced melanoma.
  Journal of hematology & oncology 2015 Tsai KK, Daud AI
• Current and Emerging Perspectives on Immunotherapy for Melanoma.
  Seminars in oncology 2015 Daud A
• Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015 Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook …
• Future of combination therapy with dabrafenib and trametinib in metastatic melanoma.
  Expert opinion on pharmacotherapy 2015 Zia Y, Chen L, Daud A
• Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
  Annals of oncology : official journal of the European Society for Medical Oncology 2015 Middleton MR, Friedlander P, Hamid O, Daud A, Plummer R, Falotico N, Chyla B, Jiang F, McKeegan E, Mostafa NM, Zhu M, Qian J, McKee M, Luo Y, Giranda VL, McArthur GA
• Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
  The Lancet. Oncology 2015 Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK,…
• Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, Drengler R, Chen C, Smith L, Espino G, Gergich K, Delgado L, Daud A, Lindia JA, Li XN, Pierce RH, Yearley JH, Wu D, Laterza …
• Pembrolizumab versus Ipilimumab in Advanced Melanoma.
  The New England journal of medicine 2015 Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, …
• The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date.
  Drugs 2015 Tsai KK, Daud AI
• The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial.
  British journal of cancer 2015 Algazi AP, Cha E, Ortiz-Urda SM, McCalmont T, Bastian BC, Hwang J, Pampaloni MH, Behr S, Chong K, Cortez B, Quiroz A, Coakley F, Liu S, Daud AI
• Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015 Daud AI, Ashworth MT, Strosberg J, Goldman JW, Mendelson D, Springett G, Venook AP, Loechner S, Rosen LS, Shanahan F, Parry D, Shumway S, Grabowsky JA, Freshwater T, Sorge C, Kang SP, Isaacs R, …
• Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity.
  Cancer cell 2014 Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, Barczak A, Rosenblum MD, Daud A, Barber DL, Amigorena S, Van't Veer LJ, Sperling AI, Wolf DM, Krummel MF
• Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial.
  Annals of oncology : official journal of the European Society for Medical Oncology 2014 Menzies AM, Ashworth MT, Swann S, Kefford RF, Flaherty K, Weber J, Infante JR, Kim KB, Gonzalez R, Hamid O, Schuchter L, Cebon J, Sosman JA, Little S, Sun P, Aktan G, Ouellet D, Jin F, Long GV, Daud A
• Involution of eruptive melanocytic nevi on combination BRAF and MEK inhibitor therapy.
  JAMA dermatology 2014 Chen FW, Tseng D, Reddy S, Daud AI, Swetter SM
• Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
  Journal of the American Academy of Dermatology 2014 Sanlorenzo M, Choudhry A, Vujic I, Posch C, Chong K, Johnston K, Meier M, Osella-Abate S, Quaglino P, Daud A, Algazi A, Rappersberger K, Ortiz-Urda S
• Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity.
  Cancer cell 2014 Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, Barczak A, Rosenblum MD, Daud A, Barber DL, Amigorena S, Van't Veer LJ, Sperling AI, Wolf DM, Krummel MF
• Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, Hamid O, Schuchter L, Cebon J, Sharfman WH, McWilliams RR, Sznol M, Lawrence DP, Gibney GT, Burris HA, Falchook GS, Algazi A, Lewis K…
• Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
  Lancet (London, England) 2014 Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, Mateus C, Postow MA, Gergich…
• Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
  The Lancet. Oncology 2014 Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski TF, Daud A, Flaherty L, Logan T, Chmielowski B, Lewis K, Kee D, Boasberg P, Yin M, Chan I, Musib L, Choong N, Puzanov I, McArthur GA
• Combinatorial approach to treatment of melanoma.
  Hematology/oncology clinics of North America 2014 Ashworth MT, Daud AI
• Melanoma, version 4.2014.
  Journal of the National Comprehensive Cancer Network : JNCCN 2014 Coit DG, Thompson JA, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daniels GA, Daud A, Dimaio D, Fleming MD, Gonzalez R, Guild V, Halpern AC, Hodi FS, Kelley MC, Khushalani NI, Kudchadkar RR, …
• Melanoma immunotherapy.
  Cancer biology & therapy 2014 Sanlorenzo M, Vujic I, Posch C, Dajee A, Yen A, Kim S, Ashworth M, Rosenblum MD, Algazi A, Osella-Abate S, Quaglino P, Daud A, Ortiz-Urda S
• Management of a patient with advanced BRAF-mutant melanoma.
  Journal of the National Comprehensive Cancer Network : JNCCN 2014 Ashworth MT, Daud A
• The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics.
  Journal of clinical pharmacology 2014 Ribas A, Zhang W, Chang I, Shirai K, Ernstoff MS, Daud A, Cowey CL, Daniels G, Seja E, O'Laco E, Glaspy JA, Chmielowski B, Hill T, Joe AK, Grippo JF
• PD-1 and PD-L1 antibodies for melanoma.
  Human vaccines & immunotherapeutics 2014 Tsai KK, Zarzoso I, Daud AI
• A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma.
  Cancer chemotherapy and pharmacology 2013 Grippo JF, Zhang W, Heinzmann D, Yang KH, Wong J, Joe AK, Munster P, Sarapa N, Daud A
• Reply to M.-E. Percival et al and L.B. Saltz.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013 Daud AI
• Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
  The New England journal of medicine 2013 Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, …
• Melanoma, version 2.2013: featured updates to the NCCN guidelines.
  Journal of the National Comprehensive Cancer Network : JNCCN 2013 Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A, Dimaio D, Fleming MD, Guild V, Halpern AC, Hodi FS, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski …
• Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.
  Proceedings of the National Academy of Sciences of the United States of America 2013 Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T, Daud AI, McCalmont TH, LeBoit PE, Ortiz-Urda S
• Removing the unknown from the carcinoma of unknown primary.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012 Daud AI
• Plasmid IL-12 electroporation in melanoma.
  Human vaccines & immunotherapeutics 2012 Cha E, Daud A
• Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
  The New England journal of medicine 2012 Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, …
• Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma.
  Expert opinion on biological therapy 2012 Daud A, Soon C, Dummer R, Eggermont AM, Hwu WJ, Grob JJ, Garbe C, Hauschild A
• Cutting edge in medical management of cutaneous oncology.
  Seminars in cutaneous medicine and surgery 2012 Chong K, Daud A, Ortiz-Urda S, Arron ST, UCSF High Risk Skin Cancer Program
• Melanoma.
  Journal of the National Comprehensive Cancer Network : JNCCN 2012 Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A, Dilawari RA, Dimaio D, Guild V, Halpern AC, Hodi FS, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski …
• Beyond BRAF in melanoma.
  Current topics in microbiology and immunology 2012 Daud A, Bastian BC
• Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Daud AI, Krishnamurthi SS, Saleh MN, Gitlitz BJ, Borad MJ, Gold PJ, Chiorean EG, Springett GM, Abbas R, Agarwal S, Bardy-Bouxin N, Hsyu PH, Leip E, Turnbull K, Zacharchuk C, Messersmith WA
• Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma.
  British journal of cancer 2011 Algazi AP, Weber JS, Andrews SC, Urbas P, Munster PN, DeConti RC, Hwang J, Sondak VK, Messina JL, McCalmont T, Daud AI
• BEAM trial: lighting the way ahead?
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 Daud AI
• Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma.
  Expert opinion on investigational drugs 2011 Munster PN, Daud AI
• Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Fishman MN, Thompson JA, Pennock GK, Gonzalez R, Diez LM, Daud AI, Weber JS, Huang BY, Tang S, Rhode PR, Wong HC
• An isolated Merkel cell carcinoma metastasis at a distant cutaneous site presenting as a second 'primary' tumor.
  Journal of cutaneous pathology 2011 Ahronowitz IZ, Daud AI, Leong SP, Shue EH, Bastian BC, McCalmont TH, Yu SS
• Cutaneous melanoma: a model to study cancer metastasis.
  Journal of surgical oncology 2011 Leong SP, Gershenwald JE, Soong SJ, Schadendorf D, Tarhini AA, Agarwala S, Hauschild A, Soon CW, Daud A, Kashani-Sabet M
• NRAS-mutant melanoma: response to chemotherapy.
  Archives of dermatology 2011 Soon CW, Algazi AP, Cha EN, Webb EM, Daud AI
• Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequences.
  Journal of computer assisted tomography 2011 Chow H, Jung A, Talbott J, Lin AM, Daud AI, Coakley FV
• Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma.
  British journal of cancer 2010 DeConti RC, Algazi AP, Andrews S, Urbas P, Born O, Stoeckigt D, Floren L, Hwang J, Weber J, Sondak VK, Daud AI
• Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma.
  Journal of immunotherapy (Hagerstown, Md. : 1997) 2010 Finkelstein SE, Carey T, Fricke I, Yu D, Goetz D, Gratz M, Dunn M, Urbas P, Daud A, DeConti R, Antonia S, Gabrilovich D, Fishman M
• Treatment of cutaneous melanoma: current approaches and future prospects.
  Cancer management and research 2010 Algazi AP, Soon CW, Daud AI
• Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma.
  Cancer chemotherapy and pharmacology 2010 Daud AI, Xu C, Hwu WJ, Urbas P, Andrews S, Papadopoulos NE, Floren LC, Yver A, Deconti RC, Sondak VK
• New horizons in melanoma treatment: targeting molecular pathways.
  Ochsner journal 2010 Soon CW, Algazi AP, Cha EN, Daud AI
• Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.
  British journal of cancer 2009 Munster PN, Marchion D, Thomas S, Egorin M, Minton S, Springett G, Lee JH, Simon G, Chiappori A, Sullivan D, Daud A
• Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
  Melanoma research 2009 Homsi J, Cubitt CL, Zhang S, Munster PN, Yu H, Sullivan DM, Jove R, Messina JL, Daud AI
• Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J, Peschel C, Schadendorf D, Garbe C, O'Day S, Daud A, White JM, Xia C, Patel K, Kirkwood JM, …
• Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Munster P, Marchion D, Bicaku E, Lacevic M, Kim J, Centeno B, Daud A, Neuger A, Minton S, Sullivan D
• Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Daud AI, Dawson J, DeConti RC, Bicaku E, Marchion D, Bastien S, Hausheer FA, Lush R, Neuger A, Sullivan DM, Munster PN
• Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Solit DB, Osman I, Polsky D, Panageas KS, Daud A, Goydos JS, Teitcher J, Wolchok JD, Germino FJ, Krown SE, Coit D, Rosen N, Chapman PB
• Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, Heller R
• State of the science 60th anniversary review: 60 Years of advances in cutaneous melanoma epidemiology, diagnosis, and treatment, as reported in the journal Cancer.
  Cancer 2008 Demierre MF, Sabel MS, Margolin KA, Daud AI, Sondak VK
• Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, Patnaik A, Papadopoulos K, Takimoto C, Bartels P, Keating A, Antonia S
• A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors.
  Cancer chemotherapy and pharmacology 2008 Verschraegen CF, Skubitz K, Daud A, Kudelka AP, Rabinowitz I, Allievi C, Eisenfeld A, Singer JW, Oldham FB
• Activated stat-3 in melanoma.
  Cancer control : journal of the Moffitt Cancer Center 2008 Messina JL, Yu H, Riker AI, Munster PN, Jove RL, Daud AI
• Melanoma: promising new discoveries and treatment modalities for difficult clinical scenarios.
  Cancer control : journal of the Moffitt Cancer Center 2008 Zager JS, Daud AI
• Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Daud AI, Mirza N, Lenox B, Andrews S, Urbas P, Gao GX, Lee JH, Sondak VK, Riker AI, Deconti RC, Gabrilovich D
• The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis.
  BMC medical genomics 2008 Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, Morris C, Xi Y, Howell P, Metge B, Samant RS, Shevde LA, Li W, Eschrich S, Daud A, Ju J, Matta J
• Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Homsi J, Simon GR, Garrett CR, Springett G, De Conti R, Chiappori AA, Munster PN, Burton MK, Stromatt S, Allievi C, Angiuli P, Eisenfeld A, Sullivan DM, Daud AI
• Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors.
  Cancer control : journal of the Moffitt Cancer Center 2007 Homsi J, Daud AI
• Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007 Münster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R, Simon G, Fishman M, Minton S, Garrett C, Chiappori A, Lush R, Sullivan D, Daud A
• The Src signaling pathway: a potential target in melanoma and other malignancies.
  Expert opinion on therapeutic targets 2007 Homsi J, Cubitt C, Daud A
• Down-regulation of pro-apoptotic genes is an early event in the progression of malignant melanoma.
  Annals of surgical oncology 2006 Jensen EH, Lewis JM, McLoughlin JM, Alvarado MD, Daud A, Messina J, Enkemann S, Yeatman TJ, Sondak VK, Riker AI
• Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2006 Simon GR, Garrett CR, Olson SC, Langevin M, Eiseman IA, Mahany JJ, Williams CC, Lush R, Daud A, Munster P, Chiappori A, Fishman M, Bepler G, Lenehan PF, Sullivan DM
• Melanoma.
  Journal of the National Comprehensive Cancer Network : JNCCN 2006 Houghton AN, Coit DG, Daud A, Dilawari RA, Dimaio D, Gollob JA, Haas NB, Halpern A, Johnson TM, Kashani-Sabet M, Kraybill WG, Lange JR, Martini M, Ross MI, Samlowski WE, Sener SF, Tanabe KK, Thompson …
• Preoperative esophageal manometry and outcome of laparoscopic adjustable silicone gastric banding.
  Surgical endoscopy 2006 Lew JI, Daud A, DiGorgi MF, Olivero-Rivera L, Davis DG, Bessler M
• Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database.
  Cancer control : journal of the Moffitt Cancer Center 2006 Khan MA, Andrews S, Ismail-Khan R, Munster PN, Brem S, King J, Reintgen DS, Sondak VK, Daud AI
• Unintentional creation of reverse peristaltic alimentary limb during Roux-en-Y gastric bypass surgery.
  Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery 2006 Schrope BA, Daud A, Bessler M
• Anti-inflammatory, anti-nociceptive and antipyretic effects of extracts of Phrygilanthus acutifolius flowers.
  Journal of ethnopharmacology 2006 Daud A, Habib N, Riera AS
• Evaluation of toxicity following electrically mediated interleukin-12 gene delivery in a B16 mouse melanoma model.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2006 Heller L, Merkler K, Westover J, Cruz Y, Coppola D, Benson K, Daud A, Heller R
• Immunotherapy as part of a multidisciplinary approach to melanoma treatment.
  Frontiers in bioscience : a journal and virtual library 2006 Riker AI, Jove R, Daud AI
• Early U.S. outcomes of laparoscopic gastric bypass versus laparoscopic adjustable silicone gastric banding for morbid obesity.
  Surgical endoscopy 2005 Kim TH, Daud A, Ude AO, DiGiorgi M, Olivero-Rivera L, Schrope B, Davis D, Inabnet WB, Bessler M
• In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates.
  Molecular cancer therapeutics 2005 Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN
• Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Marchion DC, Bicaku E, Turner JG, Daud AI, Sullivan DM, Munster PN
• Cutaneous melanoma: prognostic factors.
  Cancer control : journal of the Moffitt Cancer Center 2005 Homsi J, Kashani-Sabet M, Messina JL, Daud A
• Valproic acid alters chromatin structure by regulation of chromatin modulation proteins.
  Cancer research 2005 Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN
• Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Daud A, Valkov N, Centeno B, Derderian J, Sullivan P, Munster P, Urbas P, Deconti RC, Berghorn E, Liu Z, Hausheer F, Sullivan D
• Uncommon manifestations of common malignancies: case 3. Malignant melanoma arising from a spinal nerve root.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004 Naing A, Messina JL, Vrionis FR, Daud AI
• Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.
  Journal of cellular biochemistry 2004 Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN
• A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2002 Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, Sabbatini P, Miller V, Hensley ML, Pezzulli S, Canales C, Daud A, Spriggs DR
• Comparison of the Ca2 + currents induced by expression of three cloned alpha1 subunits, alpha1G, alpha1H and alpha1I, of low-voltage-activated T-type Ca2 + channels.
  The European journal of neuroscience 1999 Klöckner U, Lee JH, Cribbs LL, Daud A, Hescheler J, Pereverzev A, Perez-Reyes E, Schneider T
• Differential distribution of three members of a gene family encoding low voltage-activated (T-type) calcium channels.
  The Journal of neuroscience : the official journal of the Society for Neuroscience 1999 Talley EM, Cribbs LL, Lee JH, Daud A, Perez-Reyes E, Bayliss DA
• Cloning and characterization of alpha1H from human heart, a member of the T-type Ca2+ channel gene family.
  Circulation research 1998 Cribbs LL, Lee JH, Yang J, Satin J, Zhang Y, Daud A, Barclay J, Williamson MP, Fox M, Rees M, Perez-Reyes E
• Molecular characterization of a neuronal low-voltage-activated T-type calcium channel.
  Nature 1998 Perez-Reyes E, Cribbs LL, Daud A, Lacerda AE, Barclay J, Williamson MP, Fox M, Rees M, Lee JH
• Tumor suppressor gene expression during normal and pathologic myocardial growth.
  The Journal of biological chemistry 1994 Kim KK, Soonpaa MH, Daud AI, Koh GY, Kim JS, Field LJ
• Characterization of angiotensin I-converting enzyme (ACE)-containing follicles in the rat ovary during the estrous cycle and effects of ACE inhibitor on ovulation.
  Endocrinology 1990 Daud AI, Bumpus FM, Husain A